Investing in National HIV PrEP Preparedness

N Engl J Med. 2023 Mar 2;388(9):769-771. doi: 10.1056/NEJMp2216100. Epub 2023 Feb 25.

Authors

Jeremiah Johnson¹, Amy Killelea¹, Kenyon Farrow¹

Affiliation

¹ From PrEP4All, New York (J.J., K.F.); Bloomberg School of Public Health, Johns Hopkins University, Baltimore (A.K.); and Killelea Consulting, Arlington, VA (A.K.).

PMID: 36847476
DOI: 10.1056/NEJMp2216100

No abstract available

MeSH terms

Anti-HIV Agents* / administration & dosage
Anti-HIV Agents* / therapeutic use
HIV Infections* / drug therapy
HIV Infections* / prevention & control
Homosexuality, Male
Humans
Male
Pre-Exposure Prophylaxis*
United States

Substances

Anti-HIV Agents